27 April 2026
Johnson & Johnson’s IMAAVY granted FDA Priority Review for wAIHA
FDA granted Priority Review to nipocalimab sBLA for warm autoimmune hemolytic anemia after Phase 2/3 ENERGY showed durable hemoglobin responses and fatigue improvement; review ~6 months.
